Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: A randomized double-blind placebo-controlled study

European Heart Journal

Volumn 28, Issue 11, 2007, Pages 1351-1357

  Nergårdh, Anna K ^a   Rosenqvist, Mårten ^a   Nordlander, Rolf ^a   Frick, Mats ^a  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Arrhythmias; Atrial fibrillation; Cardioversion; Metoprolol

Indexed keywords

ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL; PLACEBO;

ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART BEAT; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; MALE; METOPROLOL; RECURRENCE; RETREATMENT; TREATMENT OUTCOME;

EID: 34548420203     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehl544     Document Type: Article

References (28)

1. Kannel WB, Abbott RD, Savage DD, Mc Namara PM. Epidemiological features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982;306:1018-1022.
2. Kalman JM, Tonkin AM. Atrial fibrillation: epidemiology and the risk and prevention of stroke. Pacing Clin Electrophysiol 1992;15:1332- 1346.
3. Lipkin DP, Frenneaux M, Stewart R, Joshi J, Lowe T, McKenna WJ. Delayed improvement in exercise capacity after cardioversion of atrial fibrillation to sinus rhythm. Br Heart J 1988;59:572-577.
4. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993;71:558-563.
5. Juul-Möller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990;82:1932-1939.
6. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG;. American College of Cardiology; American Heart Association; European Society of Cardiology; North American Society of Pacing and Electrophysiology. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J 2001;22:1852-1923.
7. Plewan A, Lehmann G, Ndrepepa G, Schreieck J, Alt EU, Schomig A, Schmitt C. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs. bisoprolol. Eur Heart J 2001;22:1504-1510.
8. Kühlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck O. Use of Metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2000;36:139-146.
9. Frick M, Frykman V, Jensen-Urstad M, Östergren J, Rosenqvist M. Factors predicting sucess rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. Clin Cardiol 2001;24:238-244.
10. Tieleman RG, Van Gelder IC, Crijns HJ De Kam PJ, Van Den Berg MP, Haaksma J, Vand Der Woude HJ, Allessie MA. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodelling of the atria? J Am Coll Cardiol 1998;31:167-173.
11. Wijffels M, Kirchhof C, Dorland R, Allessie M. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92:1954-1968.
12. Goette A, Honeycutt C, Langerg JJ. Electrical remodelling in atrial fibrillation. Time course and mechanisms. Circulation 1996;94:2968-2974.
13. Lombardi F, Colombo A, Basilico B, Ravaglia R, Garbin M, Vergani D, Battezzati PM, Fiorentini C. Heart rate variability and early recurrence of atrial fibrillation after electrical cardioversion. J Am Coll Cardiol 2001;37:157-162.
14. Schotten U, Duytschaever M, Ausma J, Eijsbouts S, Neuberger HR, Allessie M. Electrical and contractile remodelling during the first day of atrial fibrillation go hand in hand. Circulation 2003;107:1433-1439.
15. Bertaglia E, D'Este D, Zerbo F, Zoppo F, Delise P, Pascotto P. Success of serial external electrical cardioversion of persistent atrial fibrillation in maintaining sinus rhythm; a randomized study. Eur Heart J 2002;23:1522-1528.
16. Coumel P. Neural aspects of paroxysmal atrial fibrillation. In: Falk RH, Podrid PJ, (ed.), Atrial Fibrillation Mechanisms and management. New York, Raven Press; 1992. 109-125.
17. Campbell DL, Rasmusson RL, Comer MB, Strauss HC. The cardiac calcium-independent outward potassium current; kinetics, molecular properties, and role in ventricular repolarization. In: Zipes DP, Jalife J, (ed.), Cardiac Electrophysiology; From cell to bedside. 2nd ed. Philadelphia, Saunders; 1995. 83-96.
18. Daoud EG, Bogun F, Goyal R, Harvey M, Man KC, Strickberger SA, Morady F. Effect of atrial fibrillation on atrial refractoriness in humans. Circulation 1996;94:1600-1606.
19. Steeds RP, Birchall AS, Smith M, Channer KS. An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart 1999;82:170-175.
20. Yu WC, Lee SH, Tai CT, Tsai CF, Hsieh MH, Chen CC, Ding YA, Chang MS, Chen SA. Reversal of atrial electrical remodelling following cardioversion of long-standing atrial fibrillation in man. Cardiovasc Res 1999;42:470-476.
21. Tanabe Y, Chinushi M, Taneda K, Fujita S, Kasai H, Yamaura M, Imai S, Aizawa Y. Recovery of the right effective refractory period after cardioversion of chronic atrial fibrillation. Am J Cardiol 1999;84:1261-1264.
22. Fynn S, Todd D, Hobbs J, Armstrong K, Firzpatrick A, Garratt C. Clinical evaluation of a policy of early repeated internal cardioversion for recurrence of atrial fibrillation. J Cardiovasc Elctrophysiol 2002;13:135- 141.
23. Daoud EG, Hummel JD, Augostini R, Williams S, Kalbfleisch SJ. Effect of verapamil on immediate recurrence of atrial fibrillation. J Cardiovasc Electrophysiol 2000;11:1231-1237.
24. Villani GO, Piepoli MF, Terracciano C, Capucci A. Effects of diltiazem pretreatment on direct-current cardioversion in patients with persistent atrial fibrillation; A single-blind, randomized, controlled study. Am Heart J 2000;140:437-443.
25. Van Noord T, Tieleman RG, Bosker HA, Kingma T, van Veldhuisen DJ, Crinjns H, van Gelder IC. Beta-blockers prevent subacute recurrences of persistent atrial fibrillation only in patients with hypertension. Europace 2004;6:343-350.
26. Brundel BJ, van Gelder IC, Henning RH, Tuinenburg AE, Deelman LE, Tieleman RG, Grandjean JG, van Gilst WH, Crijns HJ. Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation. Cardiovasc Res 1999;42:443-454.
27. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990;82:1106-1116.
28. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992;20:572-532.